Escitalopram Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
Therapeutic Class
Antidepressant
Subclass
Selective Serotonin Reuptake Inhibitor (SSRI)
Speciality
Psychiatry
Schedule (India)
Schedule H
Routes
Oral
Formulations
- Tablets: 5 mg, 10 mg, 20 mg
- Oral drops/solution: 5 mg/mL (limited availability)
- Note: Fixed-dose combinations with clonazepam available — use with caution, specialist supervision preferred
Adult indications
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Major Depressive Disorder (MDD)
Adults:
| Parameter | Recommendation |
|---|---|
| Starting dose | 10 mg once daily (morning or evening) |
| Titration | May increase to 20 mg/day after ≥1 week if inadequate response |
| Usual maintenance dose | 10–20 mg/day |
| Maximum dose | 20 mg/day |
Clinical notes:
- Evaluate response after 4–6 weeks of adequate dosing
- Continue for minimum 6–9 months after remission to prevent relapse
- For recurrent depression, longer maintenance (≥2 years) may be required
2. Generalised Anxiety Disorder (GAD)
Adults:
| Parameter | Recommendation |
|---|---|
| Starting dose | 10 mg once daily (may start at 5 mg in sensitive patients) |
| Titration | Increase to 10–20 mg/day based on response after 2–4 weeks |
| Usual maintenance dose | 10 mg/day |
| Maximum dose | 20 mg/day |
Clinical notes:
- Anxiolytic effect may take 2–4 weeks to manifest
- Long-term treatment often necessary; taper gradually when discontinuing
3. Panic Disorder (with or without Agoraphobia)
Adults:
| Parameter | Recommendation |
|---|---|
| Starting dose | 5 mg once daily for first week |
| Titration | Increase to 10 mg/day after 1 week; further increase to 15–20 mg/day after 1 month if needed |
| Usual maintenance dose | 10–15 mg/day |
| Maximum dose | 20 mg/day |
Clinical notes:
- Initial worsening of anxiety may occur — warn patient
- Slower titration essential to improve tolerability
- Cognitive behavioural therapy (CBT) recommended as adjunct
4. Obsessive-Compulsive Disorder (OCD)
Adults:
| Parameter | Recommendation |
|---|---|
| Starting dose | 10 mg once daily |
| Titration | May increase to 20 mg/day after 2–4 weeks |
| Usual maintenance dose | 10–20 mg/day |
| Maximum dose | 20 mg/day |
Clinical notes:
- Higher doses may be needed; some specialists use up to 30 mg/day (off-label, specialist only)
- Long-term treatment usually required (≥1–2 years)
- Consider augmentation with antipsychotics in partial responders
5. Social Anxiety Disorder (Social Phobia)
Adults:
| Parameter | Recommendation |
|---|---|
| Starting dose | 10 mg once daily |
| Titration | May increase to 20 mg/day after 2–4 weeks if needed |
| Usual maintenance dose | 10–20 mg/day |
| Maximum dose | 20 mg/day |
Clinical notes:
- Response may take 8–12 weeks for full effect
- Combine with exposure therapy for optimal outcomes
Secondary Indications — Adults Only (Off-label)
| Indication | Dose | Duration | Notes |
|---|---|---|---|
| Post-Traumatic Stress Disorder (PTSD) — OFF-LABEL | Starting: 10 mg/day; Max: 20 mg/day | 6–12 months minimum | Specialist supervision; RCT evidence supports efficacy |
| Premenstrual Dysphoric Disorder (PMDD) — OFF-LABEL | 10 mg/day continuously OR 10 mg/day during luteal phase (day 14–28) | Cyclical or continuous; reassess every 3–6 months | International RCT evidence; used in Indian urban psychiatric practice |
| Vasomotor symptoms of menopause — OFF-LABEL | 10–20 mg/day | Variable | When HRT contraindicated; limited Indian data |
Paediatric indications
PAEDIATRIC DOSING (Specialist Only)
Primary Indications
1. Major Depressive Disorder — Adolescents (12–17 years)
| Parameter | Recommendation |
|---|---|
| Starting dose | 5 mg once daily |
| Titration | May increase to 10 mg/day after 1 week |
| Usual maintenance dose | 10 mg/day |
| Maximum dose | 20 mg/day |
Safety monitoring:
- ⚠️ Black box warning equivalent: Increased risk of suicidal ideation in early weeks of treatment
- Weekly face-to-face review for first 4 weeks, then fortnightly for next month
- Monitor for behavioural activation, agitation, self-harm ideation
Secondary Indications — Paediatrics (Off-label)
| Indication | Age | Dose | Notes |
|---|---|---|---|
| OCD — OFF-LABEL | ≥7 years | Children: 5 mg/day; Adolescents: 10 mg/day; Max: 20 mg/day | Specialist only; monitor for behavioural activation, sleep disturbance, weight changes |
| Anxiety disorders — OFF-LABEL | ≥12 years | 5–10 mg/day; Max: 20 mg/day | Limited Indian paediatric data; specialist supervision mandatory |
Paediatric Safety Statement
⚠️ Not recommended in children <12 years for depression or <7 years for any indication except under specialist supervision with documented informed consent regarding suicide risk.
Renal Adjustments
| Renal Function | Recommendation |
|---|---|
| Mild impairment (eGFR 60–89) | No adjustment required |
| Moderate impairment (eGFR 30–59) | No adjustment required |
| Severe impairment (eGFR <30) | Start at 5 mg/day; titrate cautiously |
| Haemodialysis | No specific data; use with caution at low doses |
Hepatic adjustment
Contraindications
- Known hypersensitivity to escitalopram, citalopram, or any SSRI
- Concurrent use with MAO inhibitors (including moclobemide, linezolid, methylene blue) or within 14 days of MAOI discontinuation
- Congenital long QT syndrome or known QT prolongation
- Concurrent use with pimozide
- Concurrent use with other drugs that prolong QT interval in patients with additional risk factors
Cautions
- History of seizure disorder — may lower seizure threshold
- Bipolar disorder — risk of manic switch; use with mood stabiliser
- History of suicidal ideation or self-harm — close monitoring essential
- Elderly patients — increased risk of hyponatraemia and QT prolongation
- Patients at risk of bleeding (concurrent anticoagulants, NSAIDs, antiplatelet agents)
- Narrow-angle glaucoma — may precipitate acute attack
- Hepatic impairment — reduced clearance
- Severe renal impairment
- Patients with electrolyte disturbances (hypokalaemia, hypomagnesaemia)
- Concomitant use of drugs affecting serotonin (risk of serotonin syndrome)
Pregnancy
| Aspect | Guidance |
|---|---|
| Overall safety | Low teratogenic risk based on available data; one of the preferred SSRIs in pregnancy |
| First trimester | No consistent evidence of major malformations; may continue if clinically indicated |
| Third trimester | Risk of neonatal adaptation syndrome (jitteriness, irritability, respiratory distress, feeding difficulties) |
| Preferred alternatives | Sertraline generally considered first choice in Indian obstetric psychiatry; escitalopram acceptable alternative |
| When to use | If clear maternal benefit; untreated severe depression carries significant risks |
| Monitoring | Neonatal observation for 48–72 hours post-delivery if used near term |
Lactation
| Aspect | Guidance |
|---|---|
| Compatibility | Compatible with breastfeeding |
| Excretion in milk | Low (relative infant dose <5%) |
| Preferred alternatives | Sertraline may be preferred, especially for preterm or low-birth-weight infants |
| Infant monitoring | Observe for sedation, poor feeding, irritability, weight gain |
| Clinical note | Avoid breastfeeding at peak plasma concentration (4–6 hours post-dose) if concerns |
Elderly
| Aspect | Recommendation |
|---|---|
| Starting dose | 5 mg once daily |
| Titration | Increase slowly; allow 2 weeks between dose changes |
| Maximum dose | 10 mg/day (due to QT prolongation risk at higher doses) |
| Extra risks | Hyponatraemia (SIADH), QT prolongation, falls, confusion, bleeding |
| Monitoring | Baseline ECG if cardiac history; check sodium at baseline and periodically |
Major drug interactions
| Interacting Drug | Effect | Management |
|---|---|---|
| MAO inhibitors (phenelzine, tranylcypromine, moclobemide, linezolid, methylene blue) | Serotonin syndrome — potentially fatal |
CONTRAINDICATED; wait 14 days after stopping MAOI before starting escitalopram
|
| Pimozide | Additive QT prolongation; risk of torsades de pointes |
CONTRAINDICATED
|
| Other QT-prolonging drugs (haloperidol, amiodarone, sotalol, methadone, ondansetron) | Additive QT prolongation | Avoid combination or use with ECG monitoring |
| Tramadol | Serotonin syndrome risk; lowered seizure threshold | Avoid; if essential, use lowest doses with close monitoring |
| Triptans (sumatriptan, etc.) | Serotonin syndrome risk | Use with caution; monitor for symptoms |
| Lithium | Increased serotonergic effects | Use together cautiously with monitoring |
Moderate drug interactionsModerate drug interactions
| Interacting Drug | Effect | Management |
|---|---|---|
| NSAIDs (ibuprofen, diclofenac) | Increased GI bleeding risk | Use gastroprotection if chronic use; monitor |
| Aspirin / Antiplatelet agents | Increased bleeding risk | Monitor for bruising, bleeding |
| Warfarin / Acenocoumarol | Altered anticoagulant effect; increased bleeding | Monitor INR more frequently |
| Carbamazepine, Phenytoin | Enzyme induction — reduced escitalopram levels | Monitor clinical response; may need dose increase |
| Omeprazole, Cimetidine | CYP2C19 inhibition — increased escitalopram levels | Monitor for adverse effects; consider dose reduction |
| Alcohol | Additive CNS depression | Advise avoidance |
| Metoprolol | Increased metoprolol levels (CYP2D6 substrate) | Monitor for bradycardia, hypotension |
Common Adverse effects
- Nausea (usually transient, improves in 1–2 weeks)
- Headache
- Insomnia or somnolence
- Dry mouth
- Increased sweating
- Diarrhoea or constipation
- Dizziness
- Fatigue
- Sexual dysfunction (decreased libido, anorgasmia, delayed ejaculation) — may persist
Serious Adverse effects
| Adverse Effect | Clinical Notes |
|---|---|
| QT prolongation / Torsades de pointes | Dose-dependent; higher risk at 20 mg/day and in elderly; obtain ECG if risk factors present |
| Serotonin syndrome | Presents with hyperthermia, rigidity, myoclonus, autonomic instability, altered mental status; discontinue immediately; supportive care |
| Hyponatraemia / SIADH | Especially in elderly; presents with confusion, lethargy, seizures; check sodium levels |
| Suicidal ideation | Particularly in adolescents/young adults in early weeks; close monitoring essential |
| Seizures | Rare; dose-related |
| Manic switch | In undiagnosed bipolar disorder; discontinue and reassess diagnosis |
| Abnormal bleeding | GI bleeding, ecchymoses; especially with concurrent anticoagulants/NSAIDs |
Monitoring requirements
| Phase | Parameters |
|---|---|
| Baseline | Mental status assessment, suicidality screening, BP, weight, serum sodium (especially elderly), ECG (if cardiac history, elderly, or QT risk factors) |
| Early treatment (weeks 1–4) | Weekly suicidality assessment; mood, sleep, appetite monitoring |
| During titration | Reassess response and tolerability at 2–4 weeks |
| Long-term | Serum sodium every 6–12 months in elderly; periodic assessment of treatment need; sexual function inquiry |
| Special populations | ECG in elderly receiving >10 mg/day or with cardiac risk factors |
Brands in India
- Nexito® (Sun Pharma)
- Cipralex® (Lundbeck India)
- Stalopam® (Lupin)
- Esetalo® (Abbott)
- Rexipra® (Torrent)
- Feliz-S® (Torrent)
- S-Citadep® (Cipla)
- Multiple generic formulations widely available
FDC note: Combinations with clonazepam (e.g., Nexito Plus®, Stalopam Plus®) available — use cautiously; avoid long-term benzodiazepine use
Price range (INR)
| Formulation | Approximate Price |
|---|---|
| Tablets 5 mg | ₹3–6 per tablet |
| Tablets 10 mg | Unidentified |
| Tablets 20 mg | ₹6–12 per tablet |
| Oral drops 5 mg/mL (15 mL) | ₹50–100 per bottle |
Note: Not under NLEM 2022 as individual agent. Widely available in government and private sectors.
Clinical pearls
- Escitalopram is the S-enantiomer of citalopram — approximately twice as potent; do not substitute 1:1 with citalopram (10 mg escitalopram ≈ 20 mg citalopram)
- Lowest drug interaction potential among SSRIs — minimal CYP450 inhibition; preferred when polypharmacy is unavoidable
- QT prolongation is dose-dependent — limit to 10 mg/day in elderly and those with cardiac risk factors
- Discontinuation syndrome occurs — taper over 2–4 weeks when stopping; symptoms include dizziness, paraesthesias, irritability, insomnia
- Sexual dysfunction is common and may persist — discuss proactively; consider dose reduction, drug holidays (weekend breaks — controversial), or switching to bupropion/mirtazapine if problematic
- Initial anxiety worsening in panic disorder — start at 5 mg and titrate slowly; short-term benzodiazepine cover may be needed
Version
RxIndia v1.0 — 05 May 2025
Reference
- CDSCO approved prescribing information
- National Formulary of India (NFI) 2021
- Indian Psychiatric Society Practice Guidelines
- AIIMS Psychiatry Treatment Protocols
- API Textbook of Medicine
- NIMHANS Clinical Guidelines
- IAP Guidelines (paediatric use)
- Published RCTs/meta-analyses (PTSD, PMDD — off-label basis)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.